NCT01749930View on ClinicalTrials.gov

Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Open-Angle GlaucomaOcular Hypertension
Interventions
DRUG

BOL-303259-X

BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning

DRUG

Timolol

Timolol will be administered BID once in the morning and once in the evening.

DRUG

BOL-303259-X

All participants will receive a topical ocular BOL-303259-X QD in the evening from 3 months (Visit 6) through 6 months (Visit7).

Trial Locations (1)

14609

Bausch & Lomb Inc., Rochester

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT01749930 - Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter